SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data showing slower upper-limb decline in Duchenne muscular dystrophy patients treated with deramiocel is driving attention ahead of the FDAs review. Traders largely view the findings as supportive, while some question whether open-label results resolve the agencys prior statistical concerns; talk of a short squeeze remains speculative.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Cooler-than-expected PCE inflation has eased Fed rate-hike concerns and fueled hopes for a bounce in rate-sensitive small caps. Traders remain divided on whether it can last, given IWMs recent weakness amid elevated yields and small companies financing pressures.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is drawing attention around managements business update and investor presentation, which traders read as signaling Lumilens order potential, Blazar demand and progress toward optical-engine production. Reactions are split: bullish traders see promising technology and customer interest, while skeptics say the update lacked concrete shipment evidence and worry about delays, limited disclosure and management credibility.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA administrative judges pause in the broader cannabis Schedule III rescheduling case, while considering whether to add a government report on scheduling procedures, has delayed a near-term catalyst for cannabis ETFs and operators. Traders debate whether the stay is a temporary procedural hurdle or a sign of a longer delay, with some viewing the selloff as an overreaction and others voicing concern that reform momentum has stalled.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CEO Paul Peter Taks sale of restricted shares has prompted a selloff and debate over whether the timing signals concern about Candels planned Q4 BLA filing for CAN-2409. Some traders view the sale as preplanned and remain focused on the prostate-cancer programs clinical data and regulatory progress, while others worry about execution and possible delays.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Bearish analyst commentary questioning whether AppLovins AXON/MAX ad platform is nearing a growth ceiling, alongside concerns about competition and a securities-fraud lawsuit, has weighed on shares. Traders debate that outlook against claims of accelerating e-commerce adoption and rising AXON pixel installations, with many viewing the selloff as overdone while others see growth and market-share risks.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Citis Sell downgrade, citing stretched valuation after Modernas sharp rally on positive Phase 3 melanoma-vaccine results, is driving debate. Bears see room for a pullback, while bulls defend the cancer-vaccine platform and point to detailed ESMO data as a coming catalyst.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound from a recent support zone and effort to clear near-term resistance dominate the discussion. Bulls point to dip buying and possible short covering as signs of further strength, while bears warn that a failed breakout or elevated yields could bring another pullback.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention over staged IPO lockup expirations and expected insider selling, which traders see as a potential supply overhang and source of volatility. Bulls counter that demand for Cerebras AI-inference hardware and customer deals could absorb the shares, leaving the community split between near-term caution and longer-term optimism.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

A sharp Treasury selloff and rising long-term yields are dominating discussion, with traders pointing to persistent inflation, possible further Fed hikes, oil risks, and government debt concerns. Cooler PCE readings prompted some hopes for a bond rebound, but many remain bearish and argue that one soft inflation report may not ease longer-term yield pressure.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
